Global Ticagrelor Market Grows Steadily at a CAGR of 9.2%

Introduction

Ticagrelor belongs to the class of chemical compounds known as triazolopyrimidines. It is an antiplatelet medication that prevents blood clots by reducing platelet aggregation. Ticagrelor suppresses Adenosine diphosphate (ADP) signaling by immobilizing the receptor and rendering it inactive through a novel interaction with the P2Y12 receptor. This inactivation inhibits platelet aggregation and decreases blood clots, lowering the risk of an acute coronary syndrome (ACS).

Market Dynamics

Rising Cardiovascular Disorders Drives the Global Market

Cardiovascular illnesses include damaged blood arteries, structural defects, and blood clots. These medications, including ticagrelor, inhibit platelet aggregation, used to treat cardiovascular problems. According to reports, the combination of ticagrelor and aspirin decreased the prevalence of vascular fatalities and myocardial infarctions more than the combination of clopidogrel and aspirin in patients with the acute coronary syndrome.

Globally, the prevalence of well-known risk factors such as hypertension, smoking, dyslipidemia (high cholesterol), diabetes, obesity, and an unhealthy lifestyle contributes to the high incidence of cardiovascular disease (CVD). The United States is the most obese nation in North America, with 36.2% of its population having a body mass index of more than 30.0. Thus, the rising prevalence of obesity is projected to indirectly increase the number of cardiovascular patients, thereby boosting the need for ticagrelor.

Exploring New Applications Creates Tremendous Opportunities

Patients with a history of acute coronary syndrome are mainly prescribed ticagrelor to prevent strokes. Introducing ticagrelor in various applications is one of the rising prospects for the global ticagrelor market. Ticagrelor's use in preventing various illnesses is the primary driver of market expansion. For instance, multiple uses of AstraZeneca's ticagrelor (Brilinta) are in development. The company is investigating the use of ticagrelor in treating acute ischemic stroke or transient ischemic attack and preventing vaso-occlusive crises in pediatric patients with sickle cell disease. These novel uses of ticagrelor create new market opportunities for the global ticagrelor industry.

Regional Analysis

Americas is the most significant shareholder in the global ticagrelor market and is anticipated to grow at a CAGR of 9.31% during the forecast period. This considerable rise results from a steady increase in GDP per capita and an increasing elderly population susceptible to degenerative diseases and chronic illnesses. This has led to a greater emphasis on diagnostics and therapies. In addition, the expanding patient population and residents' per capita income will push the market expansion of ticagrelor, whose significance in cardiovascular illnesses is vital. According to the American Heart Association, cardiovascular illnesses were responsible for one out of every three deaths in the United States in 2014. Likewise, cardiovascular diseases claimed over 801,000 lives in the United States in 2014. Also, the American Heart Association reports that throughout 2015, around USD 555 billion was spent in the Americas to treat cardiovascular disease. In addition, expenditures are anticipated to reach USD 1,100 billion by 2035. This increase in cardiovascular illnesses is fueling the expansion of the American market for ticagrelor.

Europe is expected to grow at a CAGR of 9.25% over the forecast period. The European market is anticipated to grow at a robust rate due to factors such as the rising patient population of strokes and cardiovascular disorders, the increasing research on antiplatelets, the availability of advanced treatment facilities, the rising healthcare expenditure, the introduction of advanced and integrated treatment options into the market, and the presence of a good healthcare infrastructure. In 2017, the European Society of Cardiology stated that there were over 6 million new instances of cardiovascular disease in the European Union and over 11 million in Europe as a whole. Additionally, Europe spent around 210 Euros on cardiovascular disease treatment in 2015. This increased healthcare spending due to cardiovascular illnesses is anticipated to benefit the market expansion.

Key Highlights

• The global ticagrelor market was valued at USD 1,672 million in 2022. It is estimated to reach USD 3,692 million by 2031, growing at a CAGR of 9.2% during the forecast period (2023–2031).
• Based on dosage, the global ticagrelor market is divided into 60 mg and 90 mg. The 90 mg segment is responsible for the highest market share and is expected to grow at a CAGR of 9.47% over the forecast period.
• Based on the route of administration, the global ticagrelor market is divided into the oral and nasogastric tube routes of administration. The oral route segment is the highest contributor to the market share and is anticipated to grow at a CAGR of 9.63% during the forecast period.
• Based on application, the global ticagrelor market is segmented into acute coronary syndromes and heart surgeries. The acute coronary syndromes segment owns the highest market share and is estimated to grow at a CAGR of 9.31% during the forecast period.
• The acute coronary syndromes segment owns the highest market share and is estimated to grow at a CAGR of 9.31% during the forecast period. The hospitals and clinics segment dominates the market share and is expected to grow at a CAGR of 9.68% for the forecast period.
• Americas is the most significant shareholder in the global ticagrelor market and is anticipated to grow at a CAGR of 9.31% during the forecast period.

Competitive Players

Competitive Players

The key players in the global ticagrelor market are AstraZeneca, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Eli Lilly, Ingelheim, Alexion, Amgen, Boehringer, Merck KGaA, and Sun Pharmaceutical Industries Ltd.

Recent Developments

Market News

• In September 2022, PhaseBio Pharmaceuticals Inc was notified that its partner SFJ Pharmaceuticals Group opted to transfer bentracimab rights to SFJ due to PhaseBio's inability to repair its Going Concern Condition. Bentracimab, formerly known as PB2452, reverses the effects of AstraZeneca Plc's (NASDAQ: AZN) Brilinta (ticagrelor).
• In January 2023, CytoSorbents Corporation announced that it had received regulatory approval from Health Canada, allowing the inclusion of Canadian sites into the pivotal Safe and Timely Antithrombotic Removal–Ticagrelor (STAR-T) randomized, controlled trial. STAR-T will help improve the drug ticagrelor's clinical outcomes during surgeries.

Segmentation

Global Ticagrelor Market: Segmentation

By Dosage

• 60 mg
• 90 mg

By Route of Administration

• Oral
• Nasogastric Tube

By Applications

• Acute Coronary Syndromes
• Heart Surgeries

By End-User

• Hospitals and Clinics
• Ambulatory Centers
• Others

By Regions

• Americas
• Europe
• Asia-Pacific
• Rest of the World (RoW)